SMMT

Latest SEC Filings & News for SMMT

3 most recent filings and news items mentioning SMMT. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/SMMT/news?limit=20"

Pull SMMT filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
RegulatoryAug 5, 2026Neutral

Summit Launches Globally Study of Ivonescimab in Bladder Cancer

Summit Therapeutics announced the HARMONi-GU1 Phase II/III trial for ivonescimab in first-line bladder cancer. The study targets a major indication for ii antibodies in oncology.

View filing at SEC.gov →
RegulatoryJul 22, 2026Positive

Ivonescimab shows improved overall survival in Phase III HARMONi trial.

Updated analysis of the global Phase III HARMONi trial demonstrates statistically significant and consistent overall survival benefits for ivonescimab plus chemotherapy in both Western and Asian NSCLC patients.

View filing at SEC.gov →
RegulatoryJun 1, 2026Positive

Summit's ivonescimab shows 70.8% ORR in Phase II colorectal cancer trial

Summit Therapeutics presented Phase II data for ivonescimab combined with chemotherapy in first-line metastatic colorectal cancer, achieving a 70.8% objective response rate with manageable safety profile. The results support continued clinical development of the bispecific antibo

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.